Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11376332 | 0.77 | ACHE (0.36) | BCHEACHELIPEMGLL | |
| SCHEMBL9260297 | 0.76 | SCN4A (0.40) | RORCALDH1A1MAPTBCHEACHE | |
| SCHEMBL9378936 | 0.72 | LMNA (0.36) | RORCALDH1A1MAPTBCHEMGLL | |
| SCHEMBL5376972 | 0.72 | ALDH1A1 (0.45) | ALDH1A1MAPT | |
| SCHEMBL5371737 | 0.72 | LMNA (0.52) | ALDH1A1MAPT | |
| SCHEMBL5378809 | 0.71 | PTPN1 (0.34) | ALDH1A1MAPT | |
| SCHEMBL5380304 | 0.71 | ALDH1A1 (0.33) | ALDH1A1MAPT | |
| SCHEMBL18179632 | 0.71 | ALDH1A1 (0.34) | ALDH1A1MAPTBCHEACHELIPE | |
| SCHEMBL5376756 | 0.70 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL7312272 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238720-B2 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7238720-B2 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1258480-B1 | Pharmaceutical use of N-Carbamoylazole derivatives | EISAI CO LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-1258480-B1 | Pharmaceutical use of N-Carbamoylazole derivatives | EISAI CO LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040186153-A1 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| US-20030060494-A1 | Pharmaceutical use of N-carbamoylazole derivatives | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1258480-A1 | Pharmaceutical use of N-Carbamoylazole derivatives | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186153-A1 | Pharmaceutical use of N-carbamoylazole derivatives | DPP4, DPP3, DPP7 | RORC 4034/4885ALDH1A1 1026/4885MAPT 3669/4885 |
| US-20030060494-A1 | Pharmaceutical use of N-carbamoylazole derivatives | DPP4, DPP3, DPP7 | RORC 4034/4885ALDH1A1 1026/4885MAPT 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.